Status:
RECRUITING
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborating Sponsors:
Università degli studi di Roma Tor Vergata
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
Conditions:
Medulloblastoma, Childhood
Eligibility:
All Genders
Up to 18 years
Phase:
EARLY_PHASE1
Brief Summary
Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therape...
Detailed Description
In this project, combining high-throughput molecular biology and translational approaches, we aim to identify the genetic and transcriptomic signatures that influence primary sensitivity and acquired ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study
Exclusion
Key Trial Info
Start Date :
November 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06959979
Start Date
November 25 2024
End Date
August 31 2026
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Gemelli Irccs
Roma, ROMA, Italy, 00151